Alagille Syndrome Treatment Market, By Drug, By Distribution Channel, By Geography

PUBLISHED: March 25, 2025

PAGES: 156 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Alagille Syndrome Treatment Market is estimated to be valued at USD 101.2 Mn in 2025 and is expected to reach USD 158.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 101.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.60%	2032 Value Projection:	USD 158.3 Mn

Alagille syndrome is a genetic disorder, in which a person have fewer bile ducts than normal in liver. Alagille syndrome can be passed from parent to child or can happen naturally. Alagille syndrome not only affects the liver, it can also cause skin, heart, facial, kidney, and eye abnormalities. While there is no known cure for Alagille syndrome, there are treatments that can help control the symptoms. Possible treatments may include medications such as Ursodeoxycholic acid, Cholestyramine, and Rifampicin that increases the flow of bile and careful management of diet to minimize nutrition and vitamin related problems. In severe cases, a liver transplant may be necessary.

Several pharmaceutical companies manufacture drugs to control the symptoms such as Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals and others. There are two drugs under the clinical trials that have the potential to treat Alagille syndrome more effectively than other medications. The two drugs are Odevixibat and Maralixibat. Furthermore, the U.S. FDA is providing support to the manufacturers by giving orphan drug designation or breakthrough designation to the new drugs.

Market Dynamics

Key players in the market are gaining huge amount of funding for the research of Alagille syndrome treatment for new drugs, which is expected to boost the Alagille syndrome treatment market growth over the forecast period. For instance, the Alagille Syndrome Alliance, an international nonprofit started in 1993, offers funding for Research Grant Program for ALGS and Science for research and development of novel therapies for Alagille syndrome treatment and encourage ALGS research in new investigators. The grant offers US$ 30,000 for each year for development of novel drug compounds.

However, lack of novel therapies is expected to restrain the Alagille syndrome treatment market growth. For instance, according to the National Organization for Rare Disorders, Alagille syndrome is caused by mutations in one of two genes - the JAG1 gene or the NOTCH2 gene. Mutations of the JAG1 gene have been identified in over 88% of cases of Alagille syndrome. Mutations in the NOTCH2 gene account for less than 1% of cases. These mutations are inherited in an autosomal dominant pattern, and finding cure for genetic disorders require extensive R&D, which is often not achieved.

Key features of the study:

This report provides in-depth analysis of the global Alagille syndrome treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global Alagille syndrome treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., and Mirum Pharmaceuticals.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global Alagille syndrome treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Alagille syndrome treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Alagille Syndrome Treatment Market, By Drug:
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
Global Alagille Syndrome Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Alagille Syndrome Treatment Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan Pharmaceuticals, Inc.
- Sanofi S.A.
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals

Product Code: CMI4398

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Diagnosis & Treatment Overview
Key Developments
PEST Analysis

4. Global Alagille Syndrome Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Alagille Syndrome Treatment Market, By Drug, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Ursodeoxycholic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

6. Global Alagille Syndrome Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends

7. Global Alagille Syndrome Treatment Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Glenmark Pharmaceuticals Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Par Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Akorn, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Albireo Pharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mirum Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ipsen Pharma
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CANbridge Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies